Rizo Aleksandra 4

What Happened Aleksandra Rizo, a director of Syndax Pharmaceuticals (SNDX), was awarded 24,000 restricted stock units (RSUs) on February 4, 2026. The Form 4 reports an acquisition price of $0.00 for the award (typical for RSU grants); no cash changed hands. These RSUs will convert into shares only if the vesting conditions are met.

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (timely filing).
• Transaction type/code: Award/Grant (A) — 24,000 RSUs reported at $0.00 per unit.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: RSUs vest one year from the grant date. Underlying shares will not be delivered and may not be transferred or sold until the earlier of separation from service, death, disability, or a change in control.
• No indication this was an open-market purchase or sale; this is a compensation grant.

Context RSU grants are a form of equity compensation and do not represent an immediate purchase or sale of stock. They typically align executive or director interests with long-term shareholder value but do not necessarily signal a personal bullish or bearish view of the stock. The reported $0 acquisition price is standard for RSU awards; the economic value will depend on SNDX’s share price at vesting.